<DOC>
	<DOCNO>NCT00486980</DOCNO>
	<brief_summary>This multinational , randomize , double-blind study compare efficacy safety two single dose regimen peramivir administer intramuscularly versus placebo adult uncomplicated acute influenza .</brief_summary>
	<brief_title>Intramuscular Peramivir Treatment Uncomplicated Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Peramivir</mesh_term>
	<criteria>Male nonpregnant female subject age ≥18 year A Rapid Antigen Test ( RAT ) perform adequate specimen collect anterior nasal swab . A negative initial RAT may repeat within one hour obtain negative result . Presence fever time screen ≥38.0 ºC ( ≥100.4 ºF ) take orally , ≥38.5 ºC ( ≥101.2 ºF ) take rectally . For subject positive RAT time screening , subject selfreport history fever feverishness within 24 hour prior screen also qualify enrollment absence document fever time screening . For subject positive RAT screening , fever define must document time screen Presence least one respiratory symptom ( cough , sore throat , nasal symptom ) severity ( mild , moderate , severe ) Presence least one constitutional symptom ( myalgia [ muscle ache ] , headache , feverishness , fatigue ) severity ( mild , moderate , severe ) Onset symptom 48 hour presentation screen Written informed consent Women pregnant breastfeed Presence clinically significant sign acute respiratory distress History severe chronic obstructive pulmonary disease ( COPD ) severe persistent asthma History congestive heart failure require daily pharmacotherapy symptom consistent New York Heart Association Class IV functional status within past 12 month History chronic renal impairment require hemodialysis and/or know suspected moderate severe renal impairment ( actual estimate creatinine clearance &lt; 50 mL/min ) Current clinical evidence active bacterial infection body site require therapy oral systemic antibiotic Presence immunocompromised status due chronic illness , previous organ transplant , use immunosuppressive medical therapy Current treatment active viral hepatitis C Presence know HIV infection CD4 count &lt; 350 cell/mm3 Current therapy oral warfarin systemic anticoagulant Receipt dose rimantadine , amantadine , zanamivir , oseltamivir 7 day prior screen Immunized influenza live attenuate virus vaccine ( FluMist® ) previous 21 day History alcohol abuse drug addiction within 1 year prior admission study Participation previous study peramivir treatment acute influenza previous participation study Participation study investigational drug within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>influenza</keyword>
</DOC>